Cargando…
Preferences for a COVID-19 vaccine in Australia
In absence of a COVID-19 vaccine, testing, contact tracing and social restrictions are among the most powerful strategies adopted around the world to slow down the spread of the pandemic. Citizens of most countries are suffering major physical, psychological and economic distress. At this stage, a s...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832016/ https://www.ncbi.nlm.nih.gov/pubmed/33358265 http://dx.doi.org/10.1016/j.vaccine.2020.12.032 |
_version_ | 1783641742713552896 |
---|---|
author | Borriello, Antonio Master, Daniel Pellegrini, Andrea Rose, John M. |
author_facet | Borriello, Antonio Master, Daniel Pellegrini, Andrea Rose, John M. |
author_sort | Borriello, Antonio |
collection | PubMed |
description | In absence of a COVID-19 vaccine, testing, contact tracing and social restrictions are among the most powerful strategies adopted around the world to slow down the spread of the pandemic. Citizens of most countries are suffering major physical, psychological and economic distress. At this stage, a safe and effective COVID-19 vaccine is the most sustainable option to manage the current pandemic. However, vaccine hesitancy by even a small subset of the population can undermine the success of this strategy. The objective of this research is to investigate the vaccine characteristics that matter the most to Australian citizens and to explore the potential uptake of a COVID-19 vaccine in Australia. Through a stated preference experiment, preferences towards a COVID-19 vaccine of 2136 residents of the Australian states and territories were collected and analysed via a latent class model. Results show that preferences for mild adverse cases, mode of administration, location of administration, price and effectiveness are heterogeneous. Conversely, preferences for immediacy and severe reactions are homogeneous, with respondents preferring a shorter period until vaccine is available and lower instances of severe side effects. The expected uptake of the vaccine is estimated under three different scenarios, with the value of 86% obtained for an average scenario. By calculating individual preferences, the willingness to pay is estimated for immediacy, effectiveness, mild and severe side effects. |
format | Online Article Text |
id | pubmed-7832016 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78320162021-01-26 Preferences for a COVID-19 vaccine in Australia Borriello, Antonio Master, Daniel Pellegrini, Andrea Rose, John M. Vaccine Article In absence of a COVID-19 vaccine, testing, contact tracing and social restrictions are among the most powerful strategies adopted around the world to slow down the spread of the pandemic. Citizens of most countries are suffering major physical, psychological and economic distress. At this stage, a safe and effective COVID-19 vaccine is the most sustainable option to manage the current pandemic. However, vaccine hesitancy by even a small subset of the population can undermine the success of this strategy. The objective of this research is to investigate the vaccine characteristics that matter the most to Australian citizens and to explore the potential uptake of a COVID-19 vaccine in Australia. Through a stated preference experiment, preferences towards a COVID-19 vaccine of 2136 residents of the Australian states and territories were collected and analysed via a latent class model. Results show that preferences for mild adverse cases, mode of administration, location of administration, price and effectiveness are heterogeneous. Conversely, preferences for immediacy and severe reactions are homogeneous, with respondents preferring a shorter period until vaccine is available and lower instances of severe side effects. The expected uptake of the vaccine is estimated under three different scenarios, with the value of 86% obtained for an average scenario. By calculating individual preferences, the willingness to pay is estimated for immediacy, effectiveness, mild and severe side effects. Elsevier Ltd. 2021-01-15 2020-12-16 /pmc/articles/PMC7832016/ /pubmed/33358265 http://dx.doi.org/10.1016/j.vaccine.2020.12.032 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Borriello, Antonio Master, Daniel Pellegrini, Andrea Rose, John M. Preferences for a COVID-19 vaccine in Australia |
title | Preferences for a COVID-19 vaccine in Australia |
title_full | Preferences for a COVID-19 vaccine in Australia |
title_fullStr | Preferences for a COVID-19 vaccine in Australia |
title_full_unstemmed | Preferences for a COVID-19 vaccine in Australia |
title_short | Preferences for a COVID-19 vaccine in Australia |
title_sort | preferences for a covid-19 vaccine in australia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832016/ https://www.ncbi.nlm.nih.gov/pubmed/33358265 http://dx.doi.org/10.1016/j.vaccine.2020.12.032 |
work_keys_str_mv | AT borrielloantonio preferencesforacovid19vaccineinaustralia AT masterdaniel preferencesforacovid19vaccineinaustralia AT pellegriniandrea preferencesforacovid19vaccineinaustralia AT rosejohnm preferencesforacovid19vaccineinaustralia |